Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery
Graphical abstract
Introduction
PAMAM dendrimers are well known carriers for different drugs including nucleic acids delivering them efficiently into tumor cells [1]. Due to the synthesis procedure dendrimers have, in contrast to other polymers, a defined molecular weight. Their low toxicity in vitro and in vivo allowed their use as delivery agent for conventional anticancer drugs, but also antibodies and nucleic acids. Early studies by Szoka et al. showed that dendrimers above generation 4 (G4) can efficiently transfect different tumor cell lines in vitro [2]. Further improved transfection properties of PAMAM dendrimers were found when utilizing dendrimers partially degraded at the amide linkage [3]. The latter is already commercialized since several years (Superfect™ from Qiagen). The ability of PAMAM dendrimers to transfect tumor cells in vivo was already demonstrated earlier when delivering oligonucleotides with PAMAM dendrimers to ascitic tumors by intraperitoneal injection [4] or plasmid DNA by intratumoral injection [5]. Here we demonstrate the intrinsic tumor targeting properties of PAMAM dendrimers generation 4 and 5 when applying PAMAM/plasmid DNA polyplexes intravenously in two different subcutaneous tumor models in mice. The plasmid type strongly influences strength and duration of transgene expression in the tumor tissue.
Section snippets
Materials
PAMAM-EDA dendrimer G4 and G5 (MW 14.215 Da and 28.826 Da, respectively; 5 mg/ml in methanol) were purchased from Sigma-Aldrich (Madrid, Spain), PAMAM-BDA dendrimer G5 (10% w/v in methanol) from Dendritic Nanotechnologies (Mount Pleasant, MI, USA). Methanol was removed by evaporation under vacuum (speedvac) and the residue dissolved at a final concentration of 4 mg/ml in sterile HBG (HEPES buffered glucose; 20 mM HEPES pH 7.5, 5% glucose (w/v)). BPEI (Sigma) was dispersed in distilled water and the
Results and discussion
PAMAM G4 and G5 both lead to complete condensation of plasmid DNA and protect DNA from enzymatic degradation [[11], [14]]. When transfecting murine Neuro2A neuroblastoma cells in vitro in the presence of serum with a plasmid expressing luciferase under the control of a CMV promoter [8], both PAMAM-EDA dendrimers G4 and G5 were able to induce significant transgene expression levels 24 h after transfection in a similar range as branched PEI (25 kDa) (Supplemental Fig. S 1A); G5 PAMAM polyplexes
Acknowledgements
This work was supported by FUN (University of Navarra Foundation), Government of Navarra (Department of Education) and Bancaja Foundation, the EC funded project GIANT, DFG SFB486 and SPP1230, and the DFG Excellence Cluster “Nanosystems Initiative Munich” (NIM). Melinda Kiss is gratefully acknowledged for technical assistance.
References (38)
- et al.
High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter
Mol. Ther.
(2001) - et al.
Activated and non-activated PAMAM dendrimers for gene delivery in vitro and in vivo
Nanomedicine
(2009) - et al.
Drug nanocarriers labeled with near-infrared-emitting quantum dots (quantoplexes): imaging fast dynamics of distribution in living animals
Mol. Ther.
(2009) - et al.
Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery
J. Control. Release
(2008) - et al.
Gene insertion and long-term expression in lung mediated by the Sleeping Beauty transposon system
Mol. Ther.
(2003) - et al.
Degradable gene carriers based on oligomerized polyamines
Eur. J. Pharm. Sci.
(2006) - et al.
Dynamics of photoinduced endosomal release of polyplexes
J. Control. Release
(2008) - et al.
Evaluation of gene promoters for liver expression by hydrodynamic gene transfer
J. Surg. Res.
(2008) - et al.
Causes and effects of heterogeneous perfusion in tumors
Neoplasia
(1999) - et al.
Dendritic vectors for gene transfection
New J. Chem.
(2007)